For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.